

04/26/01

JCS67 U.S. PTO

Please type a plus sign (+) inside the box

PTO SB 05 (2-88)
Approved for use through 09-30-2000 OMB 0651-0037
Patent and Trademark Office U.S. DEPARTMENT OF COMMERCEUTILITY
PATENT APPLICATION
TRANSMITTAL

Attorney Docket No

PC10873B SHJ

First Named Inventor or Application Identifier

L. Buckbinder

Title

ADAMTS POLYPEPTIDES, NUCLEIC ACIDS ENCODING THE
AND USES THEREOF

Express Mail Label No.

EL446402267US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents

ADDRESS TO

Commissioner for Patents
Box Patent Application
Washington, DC 20231

- 1 ☐ *Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original, and a duplicate for fee processing)
- 2 ☐ Specification [Total Pages 30]
(preferred arrangement set forth below)
- Descriptive title of the invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R&D
 - Reference in Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
- 3 ☒ Drawing(s) (35 U.S.C. 113) [Total sheets 13]
- 4 ☒ Oath or Declaration [Total pages 3]
- a ☐ Newly executed (original or copy)
- b ☐ Copy from a prior application (37 CFR §1.63(d))
(for continuation/divisional with Box 17 completed)
[Note Box 5 below]
- i ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§1.63(d)(2) and 1.33(b).
- 5 ☐ Incorporation By Reference (useable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference therein

- 6 ☐ Microfiche Computer Program (Appendix)
- 7 Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
- a ☐ Computer Readable Copy
- b ☐ Paper Copy (identical to computer copy)
- c ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

- 8 ☐ Assignment Papers (cover sheet & document(s))
- 9 ☐ 37 C.F.R. §3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)
- 10 ☐ English Translation Document (if applicable)
- 11 ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
- 12 ☒ Preliminary Amendment
- 13 ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
- 14 ☐ *Small Entity ☐ Statement filed in prior application, Status still proper and desired
(PTO/SB/09-12)
- 15 ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
- 16 ☐ Other

*NOTE FOR ITEMS 1 & 14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).

- 17 If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below, and in a preliminary amendment
- ☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No. _____
- Prior application information Examiner _____ Group/Art Unit _____

18. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Label (Insert Customer No. or Attach bar code label here) or ☐ Correspondence address below.

Name	Paul H. Ginsburg				
Address	Pfizer Inc				
Address	235 East 42nd Street, 20th Floor				
City	New York	State	New York	Zip Code	10017-5755

FEE TRANSMITTAL

Patent fees are subject to annual revision on October 1.
 These are the fees effective October 1, 1997.

Small Entity payments **must** be supported by a small entity statement
 otherwise large entity fees must be paid. See Forms PTO SB 09-12

See 37 C.F.R. §§ 1.27 and 1.28

complete if Known

Total Amount of Payment (\$ 710.00

Application Number Not yet assigned
 Filing Date Concurrent herewith
 First Named Inventor L. Buckbinder
 Examiner Name Not yet assigned
 Group/Art Unit Not yet assigned
 Attorney Docket No PC10873B

METHOD OF PAYMENT (check one)

1. ☒ The commissioner is hereby authorized to charge
 Indicated fees and credit any over payments to
 Deposit account Number Pfizer Inc
 Deposit Account Name 16-1445
☒ Charge Any Additional Fee Required Under 37 C.F.R. §§ 1.16 and 1.17
☐ Charge the Issue Fee Set in 37 C.F.R. § 1.18 at the Mailing of the Notice of Allowance.

2. ☐ Payment Enclosed:
☐ Check ☐ Money Order ☐ Other

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description	Fee Paid
101	710	201	355	Utility filing fee	710
106	320	206	160	Design filing fee	
107	490	207	245	Plant filing fee	
108	710	208	355	Reissue filing fee	
114	150	214	75	Provisional filing fee	

SUBTOTAL (1) (\$ 710.00

2. EXTRA CLAIM FEES

Extra Claims Fee from below Fee Paid
 18 0 0 = 0
 Independent Claims 3 0 0 = 0
 Multiple Dependent 0 0 = 0

Mark number previously paid, if greater. For Reissues, see below.

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description
103	14	203	9	Claims in excess of 20
102	80	202	40	Independent claims in excess of 3
104	210	204	135	Multiple dependent claim, if not paid
105	80	205	40	**Reissue independent claims over original patent
11	14	211	9	**Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$ 16

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description	Fee Paid
105	110	205	65	Surcharge - late fee or oath	
121	50	227	25	Surcharge-late provisional filing fee or cover sheet	
109	110	139	130	Non-English specification	
141	2,520	147	2,520	For filing a request for reexamination	
110	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	310	216	195	Extension for reply within second month	
117	810	217	445	Extension for reply within third month	
118	1,390	218	695	Extension for reply within fourth month	
128	1,890	228	945	Extension for reply within fifth month	
119	310	219	155	Notice of Appeal	
120	310	220	155	Filing a brief in support of an appeal	
121	270	221	135	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,240	241	620	Petition to revive - unintentional	
142	1,240	242	620	Utility issue fee (or reissue)	
143	410	243	210	Design issue fee	
144	610	244	300	Plant issue fee	
122	110	122	110	Petitions to the Commissioner	
123	50	123	50	Petitions related to provisional applications	
125	14	125	9	Submission of Information Disclosure Statement	
58	40	581	40	Recording each patent assignment per property times number of properties	
146	710	246	355	Filing a submission after final rejection (37 CFR 1.129(a))	
149	710	249	355	For each additional invention to be examined (37 CFR 1.129(b))	
Other Fee Specify:					
Other Fee Specify:					
SUBTOTAL (3) (\$ 16					

CERTIFICATE OF MAILING EXPRESS MAIL

PFIZER DOCKET NO: PC10873B

APPLICATION NUMBER: NOT YET ASSIGNED

TITLE: ADAMTS POLYPEPTIDES, NUCLEIC ACIDS ENCODING THEM, AND
USES THEREOF

APPLICANT: Leonard Buckbinder, *et al.*

"Express Mail" mailing label number EL446402267US

Date of Deposit: April 26, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.

Michelle Dungee



(Signature of person mailing paper or fee)

Pfizer, Inc
Patent Department, 20th Floor
235 East 42nd Street
New York, NY 10017-5755
(212) 733-3189